Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Annotation

Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C. Potential metabolite markers of schizophrenia. Mol Psychiatry . 2011 Oct 25 ; PubMed Abstract

Comments on Paper and Primary News
Comment by:  Michael O'Donovan, SRF Advisor
Submitted 1 November 2011 Posted 2 November 2011
  I recommend this paper

The authors suggest they have developed a biomarker test for schizophrenia based upon a handful of serum measures and one urine metabolite. The properties are said to be equivalent to a diagnostic interview. However, caution is required, and the history suggests so is a healthy dose of skepticism. But if the findings of a perfect test, or even a remotely near-perfect test, are confirmed, and particularly if they apply to very early disease, this will prove to be a landmark paper. Confirmatory studies are essential, which is why I have recommended this paper.

View all comments by Michael O'Donovan


Comment by:  Sabine BahnPaul C. Guest
Submitted 14 November 2011 Posted 14 November 2011

The development of biomarkers and the implications of using these to improve diagnostics and clinical trials are becoming more apparent, even for cases of psychiatric disorders such as schizophrenia. The regulatory health authorities now consider biomarkers as important in the pharmaceutical industry, and the Food and Drug Administration (FDA) has called for modernization and standardization of methods, tools, and techniques for the purpose of delivering better and safer drugs (Owens, 2006; Marson, 2007). The FDA has stipulated that molecules must achieve the status of validated biomarkers before they can be used in the regulatory process for clinical trials. This means that biomarkers should be measured in a test system with strict performance characteristics, that there is an established scientific proof of concept to explain the results, and that the test can be replicated with similar results in different laboratories and at different sites.

In the latest Issue of Molecular Psychiatry, Yang and coworkers describe the...  Read more


View all comments by Sabine Bahn
View all comments by Paul C. Guest

Primary News: News Brief—Metabolites in Blood and Urine: Future Laboratory Test for Schizophrenia?

Comment by:  Stephen J. Glatt
Submitted 22 November 2011 Posted 23 November 2011
  I recommend this paper

This line of work is immensely important, as the lack of reliable biomarkers presents a major barrier to the receipt of a definitive diagnosis and the initiation of treatment; ultimately, the detection of biomarkers that are present at first episode may also signal biomarkers that may be present in the prodrome and even before symptoms emerge, which might provide a basis for earlier intervention and prevention. As elegantly summarized by Drs. Bahn, Guest, and O'Donovan, these results will need replication in diverse samples before they can be capitalized upon in the form of a clinically useful test; however, it does make sense that a biomarker profile derived from multiple sources (serum and urine) might have better explanatory power than a profile derived from just one source. Similarly, the next frontier in the development of biomarker panels may involve what I've called a polyomic approach, taking into account genetic and functional genomic variation as well as metabolite variability as demonstrated here.

View all comments by Stephen J. Glatt

Submit a Comment on this Paper
Make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend this paper

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


 
 
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
 
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright